Survey of the use of thromboprophylaxis for medical patients at Christchurch Hospital

New Zealand Medical Journal

Volumn 112, Issue 1091, 1999, Pages 246-248

  Egermayer, Paul ^b   Robins, Caroline ^b   Town, G Ian ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN;

ARTICLE; CONTROLLED STUDY; FRACTURE; HEALTH SURVEY; HEART FAILURE; HEMIPARESIS; HUMAN; HYPERCOAGULABILITY; IMMOBILIZATION; INSTRUMENTATION; INTERVIEW; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MORBID OBESITY; PREGNANCY; PROPHYLAXIS; RISK FACTOR; SURGERY; THROMBOEMBOLISM;

ANTICOAGULANTS; BANDAGES; HEPARIN; HUMANS; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PULMONARY EMBOLISM; RISK FACTORS; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 0033538573     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Clagett GP. Prevention of venous thromboembolism. Overview of prevention. In: Hull R, Pineo GF, editors. Disorders of thrombosis. Philadelphia: WB Saunders & Co, 1996. p191-6.
2. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17: 257-70.
3. Egermayer P. Follow up for death or recurrence is not a reliable way of assessing the accuracy of diagnostic tests for thromboembolic disease. Chest 1997; 111: 1410-13.
4. Verstraete M. Prophylaxis of venous thromboembolism. BMJ 1997; 314: 123-5.
5. Consensus conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256: 744-9.
6. Planes A, Vochelle N, Damon JY et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
7. Bratzler DW, Raskob GE, Murray CK et al. Underuse of venous thromboembolism prophylaxis for general surgery patients. Arch Intern Med 1998; 158: 1909-12.
8. Rodgers A, Gray H, MacMahon S. Pharmacological thromboprophylaxis in hip and knee surgery: a survey of New Zealand orthopaedic surgeons. Aust NZ J Surg 1994; 64: 167-72.
9. Lindblad B, Eriksson A, Bergqvist D. Autopsy verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg 1991; 78: 849-52.
10. Bergqvist D, Lindblad B. A 30 year survey of pulmonary embolism verified at autopsy: an anlysis of 1274 surgical patients. Br J Surg 1985; 72: 105-8.
11. Anderson FA, Wheeler HB, Goldberg RJ et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151: 933-8.
12. Collins R, Scrimgeour A, Yusuf S, Peto R. Reductions of fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162-73.
13. Carter CJ. Epidemiology of venous thromboembolism. In: Hull R, Pineo GF, editors. Disorders of thrombosis. Philadelphia: WB Saunders & Co; 1996. p159-71.
14. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM et al. Enhancement by Factor V Leiden mutation of risk of deep-thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
15. Anderson FA, Wheeler HB, Goldberg RJ et al. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 591-5.
16. Salzmann EW, Davies GC. Prophylaxis of venous thromboembolism after general surgery: analysis of cost effectiveness. Ann Surg 1980; 191: 207-18.
17. Hull R, Hirsh J, Sackett DL, Stoddard GL. Cost effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 1982; 127: 990-5.
18. Oster G, Tuden R, Colditz G. Prevention of venous thromboembolism after general surgery: cost effectiveness analysis of alternative approaches to prophylaxis. Am J Med 1987; 82: 889-99.
19. Oster G, Tuden R, Colditz G. A cost effectiveness analysis of prophylaxis against deep vein thrombosis in major orthopaedic surgery. JAMA 1967; 257: 203-8.
20. Bergqvist D, Jendteg S, Lindgren B et al. Economics of general thromboembolic prophylaxis. World J Surg 1988; 12: 349-55.
21. Bergqvist D, Matzsch T. Cost benefit aspects of thromboprophylaxis. Haemostasis 1993; Supp 1: 15-19.
22. Bergqvist D, Lindgren B, Matzsch T. Cost effectiveness of preventing postoperative deep vein thrombosis. In: Hull R, Pineo GF eds. Disorders of thrombosis. Philadelphia: WB Saunders & Co; 1996. p228-33.
23. Sarasin FP, Bounameaux H. Antithrombotic strategy after total hip replacement. A coat effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. Arch Intern Med 1996; 156: 1661-8.
24. Nielsen HK, Bechgaard P, Nielsen PF et al. 178 fatal cases of pulmonary embolism in a medical department. Acta Med Scand 1981; 209: 351-5.
25. Hauch O, Jorgensen LN, Khattar SC et al. Fatal pulmonary embolism associated with surgery. An autopsy study. Acta Chir Scand 1990; 156: 747-9.
26. Sperry KL, Key CR, Andersen RE. Toward a population based assessment of death due to pulmonary embolism in New Mexico. Hum Pathol 1990; 21: 159-65.
27. Todd CJ, Freeman CJ, Camilleri-Ferrante C et al. Differences in mortality after fracture of hip: the East Anglian audit. BMJ 1995; 310: 904-8.
28. Byrne GJ, McCarthy MJ, Silverman SH. Improving uptake of prophylaxis for venous thromboembolism in general patients using prospective audit. BMJ 1996; 313: 917.
29. Anderson FA, Wheeler HB, Goldberg RJ et al. Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med 1994; 154: 669-77.